REFILE-India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact
View all comments(0)
July 10 (Reuters) - India's Glenmark Pharmaceuticals GLEN.NS said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie ABBV.N have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2001.
Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize ISB 2001 in North America, Europe, Japan and Greater China.
Subject to regulatory approvals, IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in additional milestone payments, according to the agreement.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.